TP53/KRAS variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas
Am J Clin Pathol · 2026
DOI: 10.1093/ajcp/aqaf133 ↗Kurz gefasst
Fachartikel in der Zeitschrift Am J Clin Pathol, 2026. Verfasst von Ming-Tseh Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Tumor Suppressor Protein p53, Proto-Oncogene Proteins p21(ras). Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Objective
To identify molecular markers that predict advanced disease in mucin-producing cystic neoplasms of the pancreas.
Methods
In this single-institution study, 454 pancreatic cystic fluid specimens were examined by a clinical next-generation sequencing assay.
Results
TP53 mutations were detected in 25 (7.9%) of 318 specimens harboring KRAS (BRAF or GNAS) mutation(s). Of the 25, 12 had advanced cytology/histology (positive group), and 5 did not have advanced cytology/histology (negative group). Eight cases were classified as indeterminate. Since KRAS and TP53 variant allele frequencies (VAFs) can be as low as 1% to 5%, we analyzed the TP53/KRAS VAF ratio and demonstrated a significantly higher VAF ratio in the positive group (P = .005). A VAF ratio of 1 or higher, interpreted as an indicator of a dominant TP53 clone, and concurrent TP53, CDKN2A, and SMAD4 mutations were seen only in the positive group. Lower TP53 ratios, interpreted as a minor TP53 clone, were seen in all 5 negative group specimens.
Conclusions
These results suggest that VAF ratios and concurrent mutations can be incorporated into multimodality assessments of pancreatic cysts. Longitudinal studies in patients with a lower initial TP53 VAF ratio are warranted to elucidate whether serial VAF ratios are more accurate markers than a single VAF measurement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United States.
- Department of Gastroenterology & Hepatology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United States.
- Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United States.
- Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, 21231, United States.
ORCID-Profile: Jin He, Kelly J Lafaro
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Lin, M. T., Afghani, E., Canto, M. I., Zhu, J., Ali, S. Z., Wood, L. D., He, J., Lafaro, K. J., Hruban, R. H., & Eshleman, J. R. (2026). TP53/KRAS variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqaf133
Vancouver
Lin MT, Afghani E, Canto MI, Zhu J, Ali SZ, Wood LD, et al. TP53/KRAS variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas. Am J Clin Pathol. 2026. doi:10.1093/ajcp/aqaf133
BibTeX
@article{Lin2026,
author = {Lin, Ming-Tseh and Afghani, Elham and Canto, Marcia I and Zhu, Jing and Ali, Syed Z and Wood, Laura D and He, Jin and Lafaro, Kelly J and Hruban, Ralph H and Eshleman, James R},
title = {TP53/KRAS variant allele frequency ratio predicts advanced disease in mucin-producing cystic neoplasms of the pancreas},
journal = {Am J Clin Pathol},
year = {2026},
doi = {10.1093/ajcp/aqaf133}
}
EUVIMED